Skip to Content

Clinical Trials

Last Updated: 3/26/2014

Leukemia Clinical Trials are Grouped by Disease Type:

Phase I Agents

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated 

Salvage Programs

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

    Newly Diagnosed FLT3 Mutated


    Unfit for induction chemotherapy

    Frontline AML Post-Hypomethylating Therapy for MDS

Secondary Leukemia


Supportive Care for AML

Maintenance (Patients in CR)

  • Oral AZA + BSC vs BSC as maintenance in AML in CR (2012-0866)
  • WT2725 Dosing Emulsion (2013-0404)

Myelodysplastic Syndrome (MDS) (Includes CMML)

Specific Situations

  • Hypoplastic MDS and aplastic anemia - Horse ATG (2012-0334)
  • MDS/MPN - Ruxolitinib + AZA (2012-0737)
  • FLT3Positive - Crenolanib (2012-0569)

RAS Mutated

Post Hypomethylating Agents:

Low Risk/IPSS Int-1

IPSS int-2 or high

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

Untreated - all stages 

Mimimal Residual Disease

Prior Therapy

Previously Treated with 17p Deletion

Supportive Care

Other Studies

Chronic Myelogenous Leukemia (CML)

Chronic phase

Accelerated Phase

Blastic Phase

Imatinib Intolerance/Low-grade Toxicity

Minimal Residual Disease

Supportive Care

Other Studies

Roll-over Studies

Myeloproliferative Diseases


Supportive Care

Leukemia Insights

Leukemia Insights is a quarterly newsletter for physicians and other health professionals. Insights has the latest leukemia news, research and results from ongoing clinical trials, and available leukemia programs at MD Anderson.

© 2014 The University of Texas MD Anderson Cancer Center